Metformin, Macrophage Dysfunction and Atherosclerosis.
Reads0
Chats0
TLDR
In this article, the authors discussed the future research directions of metformin: single-cell RNA sequencing, neutrophil extracellular traps (NETs), epigenetic modification, and metin-based combination drugs.Abstract:
Metformin is one of the most widely prescribed hypoglycemic drugs and has the potential to treat many diseases. More and more evidence shows that metformin can regulate the function of macrophages in atherosclerosis, including reducing the differentiation of monocytes and inhibiting the inflammation, oxidative stress, polarization, foam cell formation and apoptosis of macrophages. The mechanisms by which metformin regulates the function of macrophages include AMPK, AMPK independent targets, NF-κB, ABCG5/8, Sirt1, FOXO1/FABP4 and HMGB1. On the basis of summarizing these studies, we further discussed the future research directions of metformin: single-cell RNA sequencing, neutrophil extracellular traps (NETs), epigenetic modification, and metformin-based combination drugs. In short, macrophages play an important role in a variety of diseases, and improving macrophage dysfunction may be an important mechanism for metformin to expand its pleiotropic pharmacological profile. In addition, the combination of metformin with other drugs that improve the function of macrophages (such as SGLT2 inhibitors, statins and IL-1β inhibitors/monoclonal antibodies) may further enhance the pleiotropic therapeutic potential of metformin in conditions such as atherosclerosis, obesity, cancer, dementia and aging.read more
Citations
More filters
Journal ArticleDOI
Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms
Sheng Chen,Donghao Gan,Sixiong Lin,Yiming Zhong,Mingju Chen,Xuenong Zou,Zengwu Shao,Guozhi Xiao +7 more
TL;DR: This review provides updated information and knowledge on applications of metformin in prevention and treatment of aging and aging-related diseases.
Journal ArticleDOI
An injectable photo-cross-linking silk hydrogel system augments diabetic wound healing in orthopaedic surgery through spatiotemporal immunomodulation
TL;DR: In this paper , a photocurable methacryloxylated silk fibroin hydrogel (Sil-MA) system was developed to accelerate diabetic-wound healing via spatiotemporal immunomodulation.
Journal ArticleDOI
High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases
Simona Taverna,Alessandro Tonacci,Maria Ferraro,Giuseppe Cammarata,Giuseppina Cuttitta,Salvatore Bucchieri,Elisabetta Pace,Sebastiano Gangemi +7 more
TL;DR: This review focuses on HMGB1 redox status, localization, mechanisms of release, binding with receptors, and its activities in different oxidative stress-related chronic diseases.
Journal ArticleDOI
The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
TL;DR: In this article , a review of the role of the senescence-associated secretory phenotype (SASP) in the development of atherosclerosis is presented, focusing on a variety of novel therapeutic strategies aimed to reduce the burden of aging individuals by targeting senescent cells and inhibiting the regulatory mechanisms of the SASP.
Journal ArticleDOI
The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
TL;DR: In this article , a review of the role of the senescence-associated secretory phenotype (SASP) in the development of atherosclerosis is presented, focusing on a variety of novel therapeutic strategies aimed to reduce the burden of aging individuals by targeting senescent cells and inhibiting the regulatory mechanisms of the SASP.
References
More filters
Journal ArticleDOI
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C. Knowler,Elizabeth Barrett-Connor,Sarah E. Fowler,Richard F. Hamman,John M. Lachin,Elizabeth A. Walker,David M. Nathan +6 more
TL;DR: In this paper, the authors compared a lifestyle intervention with metformin to prevent or delay the development of Type 2 diabetes in nondiabetic individuals. And they found that the lifestyle intervention was significantly more effective than the medication.
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.
TL;DR: An updated view of the global epidemiology of type 2 diabetes mellitus, as well as dietary, lifestyle and other risk factors for T2DM and its complications are provided.